RIPK2-IN-1

CAS No. 1423186-80-4

RIPK2-IN-1( GSK2983559 | GSK-2983559 | GSK 2983559 | RIPK2-IN-1 | RIPK2 IN 1 )

Catalog No. M11784 CAS No. 1423186-80-4

A potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 93 In Stock
5MG 92 In Stock
10MG 147 In Stock
25MG 274 In Stock
50MG 500 In Stock
100MG 724 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    RIPK2-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.
  • Description
    A potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.(In Vitro):GSK2983559 active metabolite is a novel prodrug of a quinazolyl amine that inhibits RIP2 kinase. Receptor interacting protein-2 (RIP2) kinase, which is also referred to as CARD3, RICK, CARDIAK, or RIPK2, is a TKL family serine/threonine protein kinase involved in innate immune signaling. RIP2 kinase is composed of an N-terminal kinase domain and a C-terminal caspase-recruitment domain (CARD) linked via an intermediate (IM) region. The CARD domain of RIP2 kinase mediates interaction with other CARD-containing proteins, such as NODI and NOD2. NODI and NOD2 are cytoplasmic receptors which play a key role in innate immune surveillance. They recognize both gram positive and gram negative bacterial pathogens and are activated by specific peptidoglycan motifs, diaminopimelic acid (i.e., DAP) and muramyl dipeptide.
  • In Vitro
    GSK2983559 active metabolite is a novel prodrug of a quinazolyl amine that inhibits RIP2 kinase. Receptor interacting protein-2 (RIP2) kinase, which is also referred to as CARD3, RICK, CARDIAK, or RIPK2, is a TKL family serine/threonine protein kinase involved in innate immune signaling. RIP2 kinase is composed of an N-terminal kinase domain and a C-terminal caspase-recruitment domain (CARD) linked via an intermediate (IM) region. The CARD domain of RIP2 kinase mediates interaction with other CARD-containing proteins, such as NODI and NOD2. NODI and NOD2 are cytoplasmic receptors which play a key role in innate immune surveillance. They recognize both gram positive and gram negative bacterial pathogens and are activated by specific peptidoglycan motifs, diaminopimelic acid (i.e., DAP) and muramyl dipeptide.
  • In Vivo
    ——
  • Synonyms
    GSK2983559 | GSK-2983559 | GSK 2983559 | RIPK2-IN-1 | RIPK2 IN 1
  • Pathway
    Apoptosis
  • Target
    RIP kinase
  • Recptor
    RIP2
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1423186-80-4
  • Formula Weight
    458.5538
  • Molecular Formula
    C21H22N4O4S2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 32 mg/mL
  • SMILES
    O=S(C1=CC2=C(NC3=CC=C(SC=N4)C4=C3)N=CN=C2C=C1OCCO)(C(C)(C)C)=O
  • Chemical Name
    Ethanol, 2-[[4-(5-benzothiazolylamino)-6-[(1,1-dimethylethyl)sulfonyl]-7-quinazolinyl]oxy]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Linda N. Casillas, et al. Prodrugs of amino quinazoline kinase inhibitor. PCT Int. Appl. (2014), WO 2014043446 A1 20140320.
molnova catalog
related products
  • Necrostatin-5

    Necrostatin-5 (Nec-5) is a selective RIP1 kinase inhibitor and cell necrosis inhibitor that prevents the death of Fadd-deficient Jurkat cells treated with TNF-α, with an EC50 of 240 nM.

  • Necroptosis-IN-1

    Necroptosis-IN-1 is a potent necroptosis inhibitor of RIPK1. It is an analog of Necrostatin-1.

  • RIP1-IN-22

    RIP1-IN-22 is a highly potent, orally available, and brain-penetrating RIP1 kinase inhibitor with pKi of 9.04.